ClinicalTrials.gg
RecruitingNCT07602855Updated Sep 23, 2026

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

A Phase 1/2 interventional study of Risvutatug rezetecan and Ivonescimab in Neoplasms, Lung, sponsored by GlaxoSmithKline. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
184
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Lung Neoplasms by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Lung Neoplasms · GlaxoSmithKline.

Started
2026
the only one that year
Phase 1/2
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Lung Neoplasms by GlaxoSmithKline, this one is the only one that started in 2026, is the only one in phase 1/2, and was the 11th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 11 studies in Lung Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lung Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine:

  • What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects?
  • How does the body handle the drug(s)?
  • What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
03

Conditions studied

  • Neoplasms, Lung

Browse trials for

Keywords

  • Risvutatug rezetecan
  • Ris-Rez
  • Ivonescimab
  • EMBOLD
  • Neoplasms, Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  • Male or female participants at least 18 years of age (≥18 years) at the time of signing the form (ICF).
  • Participants with confirmed advanced/ solid tumors, irrespective of mutational status, as defined per cohort, as follows:

ES-SCLC

  • Histologically or cytologically confirmed SCLC (prior pathological diagnosis of complex SCLC [such as mixed SCLC and NSCLC] or transformed SCLC [NSCLC to SCLC] is not allowed)
  • ES-SCLC [per Veterans Administration Lung Study Group (VALG) criteria] at study entry Squamous NSCLC or non-squamous NSCLC
  • Histologically or cytologically confirmed Squamous or Non-squamous NSCLC.
  • Metastatic NSCLC (Stage IV), according to American Joint Committee on Cancer (AJCC) 8th edition,
  • Has at least 1 target lesion per 1.1, as determined by the investigator. that have been previously irradiated and have been shown to be progressing following irradiation may be considered as TLs.
  • Has an performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.
  • Has a of ≥ 3 months with ability to complete at least 4 cycles of study intervention.
  • Has adequate organ function
  • Is willing to use adequate (contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
  • For dose expansion only: Tumor tissue ( or a fresh biopsy) is required for all participants at screening. Tissue from a newly obtained fresh biopsy is preferred. If it is not feasible to obtain a fresh biopsy at screening, archival tumor tissue, (from the most recent biopsy (within 1 year), Formalin Fixation and Paraffin Embedding FFPE) block (preferred), or freshly cut slides is acceptable. If archival tissue is unavailable and it is not medically feasible to obtain fresh tissue, the medical monitor should be informed and exemption to the tissue requirement may be granted on a case-by-case basis. Tumor tissue is necessary for retrospective detection of B7 homolog 3 protein (B7-H3) expression and other biomarker analysis

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to baseline status preceding prior therapy (excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 1 neuropathy).

Has had major surgical procedures or serious trauma within 4 weeks prior to first dose, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator), or minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to first dose.

  • Has symptomatic Central Nervous System (CNS) , with hemorrhagic features, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to first dose, potential need for CNS radiation within the first cycle, or . Patients must have stopped or be on physiologic corticosteroid replacement therapy (prednisone ≤ 10 mg daily or equivalent).
  • Has any of the following:

    • >450 msec or QTc >480 msec for participants with bundle branch block.
    • Evidence of current arrhythmias or abnormalities (e.g., complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, PR interval >250 msec).
    • Risk factors of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old or any concomitant medications that prolong the QT interval.
    • (LVEF) \<50%.
  • Has severe, uncontrolled or active CV disorders
  • Serious or poorly controlled hypertension; adjustment of antihypertensive medications due to poor blood pressure control within 2 weeks prior to the first dose; recurrent systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg during screening period.
  • History of bleeding tendencies or coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks prior to first dose, including but not limited to:

    • Hemoptysis (defined as coughing up ≥ 1 teaspoon of fresh blood or small blood clots)
    • Transient hemoptysis associated with diagnostic bronchoscopy is allowed.
    • Nasal bleeding/epistaxis (bloody nasal discharge is allowed)
    • Current use of prophylactic or full-dose anticoagulants or anti- agents for therapeutic purposes that is not stable prior to first dose is not allowed.
  • Participants with a history of esophageal or gastric varicose vein, severe ulcer, unhealed wound, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal hemorrhage within 6 months prior to first dose.
  • History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event, as specified in National Cancer Institute- (NCI-CTCAE) 6.0, hypertensive crisis, or hypertensive encephalopathy, within 12 months prior to the first dose.
  • Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for ≥ 2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.
  • Any evidence of current Interstitial Lung Disease (ILD)/non-infectious pneumonitis OR a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids OR suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging. Examples of suspected ILD/pneumonitis by imaging include the presence of lung parenchymal fibrosis, such as combined pulmonary fibrosis and emphysema (CPFE) and any radiographic features consistent with interstitial lung abnormalities, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing.
  • Participants with moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct. Examples include severe/poorly controlled asthma or (COPD) (including acute exacerbation of COPD within 4 weeks before first dose), restrictive lung disease, significant pleural effusion (clinically significant pleural effusion on Study Day 1. Baseline oxygen saturation \< 90% on room air.) or structural lung abnormalities, pulmonary involvement from /connective tissue disorders (e.g., rheumatoid arthritis, Sjögren's, sarcoidosis), or any condition requiring continuous supplemental oxygen or causing marked respiratory impairment (e.g., dyspnea at rest, greatly reduced exercise tolerance, or significantly decreased lung function). Treatment of pleural effusions to meet eligibility is permitted.
  • History of allergy or to Ris-Rez (antibody-drug conjugate (ADC), antibody, payload [GSK5757810]). History of severe allergies (e.g., anaphylactic shock), or severe infusion-related reactions (IRRs), or idiosyncrasy to recombinant humanized or mouse proteins.
  • Has received prior anticancer therapy within 14 days of the first dose of study intervention or having to continue these medications during the study. Participants that had any macromolecular anticancer drug (including immunotherapies such as monoclonal antibodies and bispecific antibodies) within 28 days prior to the first dose of study intervention are excluded.
  • History of local radiotherapy within 2 weeks prior to the first dose of study intervention; more than 30% of bone marrow irradiation or extensive radiotherapy within 4 weeks before the first dose of study intervention
  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), or recombinant erythropoietin) within 14 days before enrollment. G-CSF prophylaxis prior to administration of Ris-Rez is permitted.
  • Has received agents within 30 days prior to first dose of study treatment (or requires long-term (30 days or longer) glucocorticoid therapy). Low-dose corticosteroids (prednisone ≤10 mg/day or equivalent) may be administered. Use of inhaled or topical steroids and prophylactic corticosteroids for procedures and pre-infusion prophylaxis are permitted.
  • Participant with history of nephrotic syndrome or Grade 3 proteinuria or protein urine >1+ on dipstick or 24-h urine protein quantitation ≥ 1.0 g at Screening.
  • History of abdominal or gastrointestinal fistula, tracheoesophageal fistula or any Grade 4 fistula, gastrointestinal perforation, or intra-abdominal abscess.
  • Has any active renal condition (e.g., requirement for dialysis, or any other significant renal condition that could affect the participant's safety). Renal obstruction successfully managed by stenting is permitted.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Phase 1: Dose escalation

    Biological: Risvutatug rezetecan · Biological: Ivonescimab

  • Experimental
    Phase 2: Dose expansion

    Biological: Risvutatug rezetecan · Biological: Ivonescimab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs)

    Time frame: Up to approximately 143 weeks

  2. Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation

    Time frame: Up to approximately 130 weeks

  3. Phase 2: Number of participants with AEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to approximately 130 weeks

  4. Phase 1 and Phase 2: Number of participants with changes in safety parameters

    Time frame: Up to approximately 143 weeks

  5. Phase 1: Number of participants with Dose Limiting Toxicities (DLT)

    Time frame: Up to 21 days

  6. Phase 1 and Phase 2: Number of participants with a change from baseline in vital signs

    Number of participants will be assessed

    Time frame: Baseline (Day -1) and up to approximately 143 weeks

  7. Phase 1 and Phase 2: Number of participants with a change from baseline in body weight

    Number of participants will be assessed

    Time frame: Baseline (Day -1) and up to approximately 143 weeks

  8. Phase 1 and Phase 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)

    Number of participants will be assessed

    Time frame: Baseline (Day -1) and up to approximately 143 weeks

  9. Phase 1 and Phase 2: Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG) and Echocardiogram (ECHO)]

    Number of participants will be assessed

    Time frame: Baseline (Day -1) and up to approximately 143 weeks

  10. Phase 1 and Phase 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status

    Number of participants will be assessed

    Time frame: Baseline (Day -1) and up to approximately 143 weeks

  11. Phase 2:Confirmed Objective Response Rate (cORR)

    cORR is defined as the proportion of participants who have confirmed Complete Response (CR) or Partial Response (PR), assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1

    Time frame: Up to approximately 143 weeks

Secondary outcomes

  1. Phase 1: Maximum observed plasma concentration (Cmax) of Ris-Rez, rezetecan and ivonescimab

    Time frame: Up to approximately 169 weeks

  2. Phase 1: Time to reach maximum concentration (Tmax) of Ris-Rez, GSK5757810 and ivonescimab

    Time frame: Up to approximately 169 weeks

  3. Phase 1: Area under the curve (AUC) of Ris-Rez, GSK5757810 and ivonescimab

    Time frame: Up to approximately 169 weeks

  4. Phase 1: Trough concentration (Ctrough) of Ris-Rez, GSK5757810 and ivonescimab

    Time frame: Up to approximately 169 weeks

  5. Phase 1: Confirmed Objective Response Rate (cORR)

    cORR is defined as the proportion of participants who have confirmed Complete Response (CR) or Partial Response (PR), assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1

    Time frame: Up to approximately 143 weeks

  6. Phase 1 and Phase 2:Disease control rate at 12 weeks (DCR12)

    DCR12 is as the proportion of participants who have achieved CR or PR, or stable disease (SD) for a duration of at least 11 weeks, per RECIST 1.1 by investigator assessment

    Time frame: At week 12

  7. Phase 1and Phase 2: Duration of Response (DoR)

    DoR is defined as the time from the date of first documented objective response (CR/PR) per RECIST 1.1 by investigator assessment to the date of first documented PD or death due to any cause, whichever comes first

    Time frame: Up to approximately 169 weeks

  8. Phase 2: Progression-free survival (PFS)

    PFS is defined as the time from the date of first dose until the earliest date of documented disease progression according to RECIST 1.1 per investigator assessment

    Time frame: Up to approximately 169 weeks

  9. Phase 1 and Phase 2: Overall Survival (OS)

    OS is defined as the time from first dose to death from any cause

    Time frame: Up to approximately 169 weeks

  10. Phase 2: Observed plasma concentration of Ris-Rez, GSK5757810 and ivonescimab

    Time frame: Up to approximately 169 weeks

  11. Phase 2: Number of participants with Anti-drug antibodies (ADA) and Neutralizing antibody (NAb) for Ris-Rez and ivonescimab

    Time frame: Up to approximately 169 weeks

  12. Phase 2: Titers of ADA to Ris-Rez and ivonescimab

    Time frame: Up to approximately 169 weeks

07

Study locations

4 of 4 sites recruiting
  • GSK Investigational Site
    Los Angeles, California 90027, United States
    Recruiting
  • GSK Investigational Site
    Wilson, North Carolina 27893-3484, United States
    Recruiting
  • GSK Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • GSK Investigational Site
    Osaka, 573-1191, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2029, 33 months after the start.

Of 79 industry-sponsored phase 1/2 interventional studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 82. This study's planned 33 months is below that.

Counting every sponsor, half of 157 studies reached it within 54 months; a quarter within 40 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Sep 9, 2026
Primary completionEst.
Jun 22, 2029
CompletionEst.
Dec 24, 2029
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07602855
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Sep 9, 2026
Primary completion
Jun 22, 2029 (estimated)
Completion
Dec 24, 2029 (estimated)
Last update
Sep 23, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Ivonescimab

Start the discussion